Eucrisa and Opzelura Comparison

Eucrisa ®(crisaborole)	Opzelura®(ruxolitinib)
Prescription Only Eucrisa is used to treat mild to moderate eczema in adults and children at least three months old. Eucrisa is FDA approved for the following indications: atopic...	Prescription Only Opzelura is for mild to moderate eczema and nonsegmental vitiligo. It is intended for short-term and non-continuous use in people aged 12 and above who are not immunocompromised...
Administration
Topical. Learn more.	Topical. Learn more.
Dosing
Apply a thin layer twice daily to affected areas. Not for ophthalmic, oral, or intravaginal use.. Learn more.	Do not use more than one 60 gram tube per week or one 100 gram tube per 2 weeks. Not for ophthalmic, oral, or intravaginal use. Atopic Dermatitis: Apply a thin layer twice daily to affected areas of up to 20% body surface area. . Learn more.
Latin Shorthand
Apply a thin layer BID to affected areas.. Learn more.	Apply a thin layer BID to affected areas up to 20% body surface area.. Learn more.
Out-Of-Pocket Costs With Copay Card
$10 (with insurance) or $100 (without insurance). Learn more.	$0. Learn more.
Annual Cap
$970 per tube, $3,880 per calendar year. Learn more.	$1,755 per tube, $10,000 per calendar year. Learn more.
Assistance Expiration
12/31/2023. Learn more.	12/31/2023. Learn more.
Generics
No lower-cost generic available	No lower-cost generic available
Adverse Reactions
The most common adverse reaction occurring in ≥1% in subjects is application site pain. . Learn more.	In atopic dermatitis, the most common adverse reactions (incidence ≥ 1%) are nasopharyngitis, diarrhea, bronchitis, ear infection, eosinophil count increased, urticaria, folliculitis, tonsillitis, and rhinorrhea. In nonsegmental vitiligo, the most common adverse reactions (incidence ≥ 1%) are application site acne, application site pruritus, nasopharyngitis, headache, urinary tract infection, application site erythema, and pyrexia.. Learn more.
Mechanism of Actions (MoA)
Phosphodiesterase 4 inhibitors. Learn more.	Protein kinase inhibitors. Learn more.
Special Populations
What is the risk of using EUCRISA during pregnancy? There is no available data with EUCRISA in pregnant women to inform the drug-associated risk for major birth defects and miscarriage. In animal reproduction studies, no adverse developmental effects were observed with oral administration of crisaborole in pregnant rats and rabbits during organogenesis at doses up to 3 and 2 times, respectively, the maximum recommended human dose (MRHD). All pregnancies carry some risk of birth defect, loss, or other adverse outcomes. The background risk of major birth defects in the U.S. general population is 2% to 4% and of miscarriage is 15% to 20% of clinically recognized pregnancies. Is EUCRISA safe to use while breastfeeding? There is no information available on the presence of EUCRISA in human milk, the effects of the drug on the breastfed infant or the effects of the drug on milk production after topical application of EUCRISA to women who are breastfeeding. EUCRISA is systemically absorbed. The lack of clinical data during lactation precludes a clear determination of the risk of EUCRISA to a breastfed infant. Therefore, the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for EUCRISA and any potential adverse effects on the breastfed infant from EUCRISA or from the underlying maternal condition. Is EUCRISA safe for pediatric use? The safety and effectiveness of EUCRISA have been established in pediatric patients ages 3 months and older for topical treatment of mild to moderate atopic dermatitis. Use of EUCRISA in this age group is supported by data from two 28-day adequate, vehicle-controlled safety and efficacy trials which included 1,313 pediatric subjects ages 2 years to 17 years of whom 874 received EUCRISA. The most commonly reported adverse reaction in subjects 2 years and older was application site pain. Additionally, use of EUCRISA in pediatric patients ages 3 months to less than 2 years was supported by data from a 28-day open-label, safety and pharmacokinetics (PK) trial in 137 subjects. No new safety signals were identified in subjects 3 months to less than 2 years of age. The safety and effectiveness of EUCRISA in pediatric patients below the age of 3 months have not been established. What is the geriatric use of EUCRISA? Clinical studies of EUCRISA did not include sufficient numbers of subjects age 65 and over to determine whether they respond differently from younger subjects.	Is there a pregnancy exposure registry for OPZELURA? Yes, there is a pregnancy registry that monitors pregnancy outcomes in pregnant persons exposed to OPZELURA during pregnancy. Pregnant persons exposed to OPZELURA and healthcare providers should report OPZELURA exposure by calling 1-855-463-3463. What is the risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes with OPZELURA? Available data from pregnancies reported in clinical trials with OPZELURA are not sufficient to evaluate a drug-associated risk for major birth defects, miscarriage, or other adverse maternal or fetal outcomes. In animal reproduction studies, oral administration of ruxolitinib to pregnant rats and rabbits during the period of organogenesis resulted in adverse developmental outcomes at doses associated with maternal toxicity. The background risks of major birth defects and miscarriage for the indicated populations are unknown. All pregnancies carry some risk of birth defects, loss, or other adverse outcomes. What is the recommended duration of not breastfeeding during treatment with OPZELURA? Because of the serious adverse findings in adults, including risks of serious infections, thrombocytopenia, anemia, and neutropenia, advise women not to breastfeed during treatment with OPZELURA and for approximately four weeks after the last dose (approximately 5-6 elimination half-lives). What is the safety and effectiveness of OPZELURA in pediatric patients? The safety and effectiveness of OPZELURA for the topical treatment of mild-to-moderate atopic dermatitis have been established in pediatric patients aged 12 to 17 years of age. Use of OPZELURA in this age group is supported by evidence from clinical trials. The safety and effectiveness of OPZELURA in pediatric patients younger than 12 years of age with atopic dermatitis have not been established. The safety and effectiveness of OPZELURA for the topical treatment of nonsegmental vitiligo have been established in pediatric patients aged 12 to 17 years of age. Use of OPZELURA in this age group is supported by evidence from clinical trials. The safety and effectiveness of OPZELURA in pediatric patients younger than 12 years of age with nonsegmental vitiligo have not been established. Oral administration of ruxolitinib to juvenile rats resulted in effects on growth and bone measures. Is there a difference in safety and effectiveness of OPZELURA between geriatric and younger patients? No clinically meaningful differences in safety or effectiveness were observed between subjects less than 65 years and subjects 65 years and older.

Eucrisa ®(crisaborole)

Opzelura®(ruxolitinib)

Prescription Only

Eucrisa is used to treat mild to moderate eczema in adults and children at least three months old. Eucrisa is FDA approved for the following indications: atopic...

Prescription Only

Opzelura is for mild to moderate eczema and nonsegmental vitiligo. It is intended for short-term and non-continuous use in people aged 12 and above who are not immunocompromised...

Dosage & Administration

Administration

Topical. Learn more.

Dosing

Apply a thin layer twice daily to affected areas. Not for ophthalmic, oral, or intravaginal use.. Learn more.

Do not use more than one 60 gram tube per week or one 100 gram tube per 2 weeks. Not for ophthalmic, oral, or intravaginal use. Atopic Dermatitis: Apply a thin layer twice daily to affected areas of up to 20% body surface area. . Learn more.

Latin Shorthand

Apply a thin layer BID to affected areas.. Learn more.

Apply a thin layer BID to affected areas up to 20% body surface area.. Learn more.

Financial Assistance

Out-Of-Pocket Costs With Copay Card

$10 (with insurance) or $100 (without insurance). Learn more.

$0. Learn more.

Annual Cap

$970 per tube, $3,880 per calendar year. Learn more.

$1,755 per tube, $10,000 per calendar year. Learn more.

Assistance Expiration

12/31/2023. Learn more.

Generics

No lower-cost generic available

Physician Advisory

Adverse Reactions

The most common adverse reaction occurring in ≥1% in subjects is application site pain. . Learn more.

In atopic dermatitis, the most common adverse reactions (incidence ≥ 1%) are nasopharyngitis, diarrhea, bronchitis, ear infection, eosinophil count increased, urticaria, folliculitis, tonsillitis, and rhinorrhea. In nonsegmental vitiligo, the most common adverse reactions (incidence ≥ 1%) are application site acne, application site pruritus, nasopharyngitis, headache, urinary tract infection, application site erythema, and pyrexia.. Learn more.

Mechanism of Actions (MoA)

Phosphodiesterase 4 inhibitors. Learn more.

Protein kinase inhibitors. Learn more.

Special Populations

What is the risk of using EUCRISA during pregnancy?

There is no available data with EUCRISA in pregnant women to inform the drug-associated risk for major birth defects and miscarriage. In animal reproduction studies, no adverse developmental effects were observed with oral administration of crisaborole in pregnant rats and rabbits during organogenesis at doses up to 3 and 2 times, respectively, the maximum recommended human dose (MRHD). All pregnancies carry some risk of birth defect, loss, or other adverse outcomes. The background risk of major birth defects in the U.S. general population is 2% to 4% and of miscarriage is 15% to 20% of clinically recognized pregnancies.

Is EUCRISA safe to use while breastfeeding?

There is no information available on the presence of EUCRISA in human milk, the effects of the drug on the breastfed infant or the effects of the drug on milk production after topical application of EUCRISA to women who are breastfeeding. EUCRISA is systemically absorbed. The lack of clinical data during lactation precludes a clear determination of the risk of EUCRISA to a breastfed infant. Therefore, the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for EUCRISA and any potential adverse effects on the breastfed infant from EUCRISA or from the underlying maternal condition.

Is EUCRISA safe for pediatric use?

The safety and effectiveness of EUCRISA have been established in pediatric patients ages 3 months and older for topical treatment of mild to moderate atopic dermatitis. Use of EUCRISA in this age group is supported by data from two 28-day adequate, vehicle-controlled safety and efficacy trials which included 1,313 pediatric subjects ages 2 years to 17 years of whom 874 received EUCRISA. The most commonly reported adverse reaction in subjects 2 years and older was application site pain. Additionally, use of EUCRISA in pediatric patients ages 3 months to less than 2 years was supported by data from a 28-day open-label, safety and pharmacokinetics (PK) trial in 137 subjects. No new safety signals were identified in subjects 3 months to less than 2 years of age. The safety and effectiveness of EUCRISA in pediatric patients below the age of 3 months have not been established.

What is the geriatric use of EUCRISA?

Clinical studies of EUCRISA did not include sufficient numbers of subjects age 65 and over to determine whether they respond differently from younger subjects.

Is there a pregnancy exposure registry for OPZELURA?

Yes, there is a pregnancy registry that monitors pregnancy outcomes in pregnant persons exposed to OPZELURA during pregnancy. Pregnant persons exposed to OPZELURA and healthcare providers should report OPZELURA exposure by calling 1-855-463-3463.

What is the risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes with OPZELURA?

Available data from pregnancies reported in clinical trials with OPZELURA are not sufficient to evaluate a drug-associated risk for major birth defects, miscarriage, or other adverse maternal or fetal outcomes. In animal reproduction studies, oral administration of ruxolitinib to pregnant rats and rabbits during the period of organogenesis resulted in adverse developmental outcomes at doses associated with maternal toxicity. The background risks of major birth defects and miscarriage for the indicated populations are unknown. All pregnancies carry some risk of birth defects, loss, or other adverse outcomes.

What is the recommended duration of not breastfeeding during treatment with OPZELURA?

Because of the serious adverse findings in adults, including risks of serious infections, thrombocytopenia, anemia, and neutropenia, advise women not to breastfeed during treatment with OPZELURA and for approximately four weeks after the last dose (approximately 5-6 elimination half-lives).

What is the safety and effectiveness of OPZELURA in pediatric patients?

The safety and effectiveness of OPZELURA for the topical treatment of mild-to-moderate atopic dermatitis have been established in pediatric patients aged 12 to 17 years of age. Use of OPZELURA in this age group is supported by evidence from clinical trials. The safety and effectiveness of OPZELURA in pediatric patients younger than 12 years of age with atopic dermatitis have not been established. The safety and effectiveness of OPZELURA for the topical treatment of nonsegmental vitiligo have been established in pediatric patients aged 12 to 17 years of age. Use of OPZELURA in this age group is supported by evidence from clinical trials. The safety and effectiveness of OPZELURA in pediatric patients younger than 12 years of age with nonsegmental vitiligo have not been established. Oral administration of ruxolitinib to juvenile rats resulted in effects on growth and bone measures.

Is there a difference in safety and effectiveness of OPZELURA between geriatric and younger patients?

No clinically meaningful differences in safety or effectiveness were observed between subjects less than 65 years and subjects 65 years and older.

Eucrisa ® Alternatives